Back to Search
Start Over
MUC1-Targeted Radiopharmaceuticals in Cancer Imaging and Therapy
- Source :
- Molecular Pharmaceutics. 18:1842-1861
- Publication Year :
- 2021
- Publisher :
- American Chemical Society (ACS), 2021.
-
Abstract
- Mucin 1 (MUC1) is a large, transmembrane mucin glycoprotein overexpressed in most adenocarcinomas and plays an important role in tumor progression. Regarding its cellular distribution, biochemical features, and function, tumor-related MUC1 varies from the MUC1 expressed in normal cells. Therefore, targeting MUC1 for cancer immunotherapy and imaging can exploit the difference between cancerous and normal cells. Radiopharmaceuticals have a potential use as carriers for the delivery of radionuclides to tumors for a diagnostic imaging and radiotherapy. Several radiolabeled targeting molecules like peptides, antibodies, and aptamers have been efficiently demonstrated in detecting and treating cancer by targeting MUC1. This review provides a brief overview of the current status of developments and applications of MUC1-targeted radiopharmaceuticals in cancer imaging and therapy.
- Subjects :
- Aptamer
medicine.medical_treatment
Pharmaceutical Science
02 engineering and technology
Adenocarcinoma
digestive system
030226 pharmacology & pharmacy
Mice
03 medical and health sciences
0302 clinical medicine
Cancer immunotherapy
Antigens, Neoplasm
Cell Line, Tumor
Neoplasms
Drug Discovery
Animals
Humans
Medicine
skin and connective tissue diseases
neoplasms
MUC1
Drug Carriers
business.industry
Mucin-1
Mucin
Cancer
Immunotherapy
021001 nanoscience & nanotechnology
medicine.disease
Xenograft Model Antitumor Assays
biological factors
digestive system diseases
Molecular Imaging
Radiation therapy
Disease Models, Animal
Tumor progression
Cancer research
Molecular Medicine
Radiopharmaceuticals
0210 nano-technology
business
Subjects
Details
- ISSN :
- 15438392 and 15438384
- Volume :
- 18
- Database :
- OpenAIRE
- Journal :
- Molecular Pharmaceutics
- Accession number :
- edsair.doi.dedup.....9b2df97a7d8227b2696ebfc319318232
- Full Text :
- https://doi.org/10.1021/acs.molpharmaceut.0c01249